Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

188.34USD
15 Feb 2019
Change (% chg)

$1.66 (+0.89%)
Prev Close
$186.68
Open
$188.43
Day's High
$189.10
Day's Low
$185.99
Volume
1,360,583
Avg. Vol
1,350,803
52-wk High
$210.18
52-wk Low
$163.31

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 16.90 30.48 33.70
EPS (TTM): 11.00 -- --
ROI: 11.98 14.95 14.45
ROE: 26.43 16.27 15.96

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

NEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

11 Feb 2019

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

NEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

11 Feb 2019

Sanofi and Regeneron cut list price of cholesterol drug by 60 pct

NEW YORK, Feb 11 Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

11 Feb 2019

EXCLUSIVE-Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva

NEW YORK, Feb 1 A top U.S. pharmacy benefit manager (PBM) owned by UnitedHealth Group Inc has included new migraine drugs from Amgen Inc and Eli Lilly and Co as preferred treatments on its lists of covered drugs, according to an OptumRx client note viewed by Reuters.

01 Feb 2019

REFILE-EXCLUSIVE-Optum to cover Amgen, Eli Lilly migraine drugs, exclude Teva

NEW YORK, Feb 1 Optum, a top U.S. pharmacy benefit manager owned by UnitedHealth Group Inc, has included new migraine drugs from Amgen Inc and Eli Lilly and Co as preferred treatments on its lists of covered drugs, according to an Optum client note viewed by Reuters.

01 Feb 2019

Amgen 2019 forecast falls short of expectations, shares dip

Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

30 Jan 2019

Amgen 2019 forecast falls short of expectations, shares dip

Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

29 Jan 2019

UPDATE 2-Amgen 2019 forecast falls short of expectations, shares dip

Jan 29 Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

29 Jan 2019

Amgen quarterly profit tops Street view, 2019 forecast falls short

Jan 29 Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit as sales rose and tax expense fell, but competition for older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

29 Jan 2019

Amgen's postmenopausal osteoporosis drug wins FDA panel backing

An advisory panel to the U.S. Food and Drug Administration said on Wednesday that benefits of Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture outweighed its risks and overwhelmingly voted for the drug's approval.

16 Jan 2019

Earnings vs. Estimates